KCG Holdings Inc. acquired a new stake in shares of Matinas BioPharma Holdings Inc (NASDAQ:MTNB) during the first quarter, according to its most recent 13F filing with the SEC. The firm acquired 69,510 shares of the company’s stock, valued at approximately $193,000. KCG Holdings Inc. owned approximately 0.08% of Matinas BioPharma Holdings as of its most recent filing with the SEC.
Several other institutional investors also recently bought and sold shares of the stock. Raymond James Financial Services Advisors Inc. bought a new position in Matinas BioPharma Holdings during the first quarter valued at about $1,781,000. Alliance Wealth Management Group bought a new position in Matinas BioPharma Holdings during the first quarter valued at about $1,162,000. Hyman Charles D bought a new position in Matinas BioPharma Holdings during the first quarter valued at about $221,000. Segantii Capital Management Ltd bought a new position in Matinas BioPharma Holdings during the first quarter valued at about $166,000. Finally, Spark Investment Management LLC bought a new position in Matinas BioPharma Holdings during the first quarter valued at about $105,000.
Matinas BioPharma Holdings Inc (NASDAQ MTNB) traded up 3.57% during trading on Friday, hitting $1.16. 376,468 shares of the stock traded hands. The company’s market cap is $106.02 million. Matinas BioPharma Holdings Inc has a 12 month low of $0.63 and a 12 month high of $3.99. The company’s 50 day moving average price is $1.79 and its 200 day moving average price is $2.59.
Matinas BioPharma Holdings (NASDAQ:MTNB) last issued its earnings results on Tuesday, May 16th. The company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.04) by $0.21. Matinas BioPharma Holdings had a negative return on equity of 1,227.85% and a negative net margin of 30,034.20%. The business had revenue of $0.02 million for the quarter. On average, equities research analysts anticipate that Matinas BioPharma Holdings Inc will post ($0.26) EPS for the current fiscal year.
Several equities analysts have recently issued reports on MTNB shares. Maxim Group restated a “buy” rating and set a $6.00 price objective on shares of Matinas BioPharma Holdings in a report on Monday, June 26th. Roth Capital started coverage on shares of Matinas BioPharma Holdings in a report on Monday, July 10th. They set a “buy” rating and a $9.00 price objective on the stock.
About Matinas BioPharma Holdings
Matinas BioPharma Holdings, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in identifying and developing therapeutics for the treatment of serious and life-threatening infections. It is engaged in developing a pipeline of product and development candidates, with an initial focus on serious fungal and bacterial infections.
Want to see what other hedge funds are holding MTNB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Matinas BioPharma Holdings Inc (NASDAQ:MTNB).
Receive News & Ratings for Matinas BioPharma Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Matinas BioPharma Holdings Inc and related companies with MarketBeat.com's FREE daily email newsletter.
